Understanding B-Lactam Resistance in Acinetobacter baumannii

了解鲍曼不动杆菌中的 B-内酰胺耐药性

• 批准号: 8865533
• 负责人: ROBERT A. BONOMO
• 金额: $ 32.34万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8865533
• 关键词: Acinetobacter; Acinetobacter baumannii; Active Sites; Address; Affect; Amino Acid Sequence; Amino Acids; Antibiotics; Area; Bacteria; Binding; Biochemical; Boronic Acids; Calorimetry; Cataloging; Catalogs; Cephalosporinase; Cephalosporins; Chemicals; Circular Dichroism; Collaborations; Communicable Diseases; Complement; Complex; Data; Development; Drug Design; Enzymes; Evolution; Family Planning; Funding; Genetic; Goals; Hand; Health; Hospitals; Investigation; Kinetics; Knock-out; Knowledge; Laboratories; Lactamase; Lactams; Learning; Libraries; Maps; Measurement; Mediating; Modification; Molecular; Molecular Genetics; Monobactams; Mutagenesis; Paper; Patients; Penicillin Resistance; Personal Communication; Phenotype; Physicians; Plague; Play; Positioning Attribute; Predisposition; Production; Property; Proteins; Publishing; Renaissance; Research Personnel; Resistance; Roentgen Rays; Role; Side; Site-Directed Mutagenesis; Specificity; Structure; Structure-Activity Relationship; Sulfonamides; System; Testing; Variant; Water; Work; antimicrobial; base; biapenem; chemotherapy; comparative; design; efflux pump; enzyme structure; experience; genome sequencing; infancy; inhibitor/antagonist; insight; interest; multidisciplinary; novel; resistance mechanism; web site

DESCRIPTION (provided by applicant): �-Lactam resistance in Acinetobacter baumannii presents one of the greatest challenges to contemporary antimicrobial chemotherapy. The production of �-lactamases is singularly responsible for this phenotype. Added to this "arsenal of resistance" is the emerging importance of efflux pumps. The goal of this R01 renewal is to embark upon a multidisciplinary and integrative approach to gain insight into the molecular details that result in �-lactam resistance by studying the AmpC cephalosporinase, ADC-7 (Acinetobacter derived cephalosporinase), and the efflux pumps of A. baumannii. Our work addresses the most important barriers to successful �-lactam therapy. To address this significant problem, we will analyze how specific boronic acid inhibitors (BAIs) that contain different R1 and R2 side chains inactivate ADC-7. Our approach will entail kinetic and biophysical (isothermal calorimetry, protein thermal stability, and circular dichroism) measurements that will complement structural characterization. Together, we will gain unique insights into the mechanism of inactivation, the energetic requirements that define a potent inhibitor, and understand the evolution of �-lactamase specificity. Once the BAIs are characterized and the structures of each BAI/ADC-7 complex are determined, we will also test our conclusions by performing site-directed mutagenesis of amino acid residues that interact with the BAI and test the impact of these changes on susceptibility, kinetics, protein stability, and structure. This comprehensive approach will reveal which amino acid positions are: (a) important for binding of BAI and �-lactam compounds; and (b) critical for enzyme structure, stability, and/or function. Our efforts will provide a rational basis for the development and optimization of novel BAIs. In concert with these investigations, we will define the role of heretofore uncharacterized efflux pumps in �-lactam/BAI resistance. Using "knockouts" of AdeABC and AdeIJK (adeABC/adeIJK), we will explore the role of "secondary" efflux pumps and transporters in �-lactam resistance. Achieving these aims in two areas affecting �-lactam resistance will help us design more potent �-lactams against A. baumannii. Additionally, our work is a "first step" to understanding why the efflux systems of A. baumannii present a formidable barrier to antibiotics. Integrating this knowledge will provide the necessary insights regarding �-lactam resistance that will assist medicinal chemists and physicians faced with this serious infectious disease threat.

描述（由申请人提供）：鲍曼不动杆菌中的β-内酰胺耐药性是当代抗菌化学疗法面临的最大挑战之一，β-内酰胺酶的产生是造成这种表型的唯一原因。 R01 更新的目标是采用多学科和综合方法来深入了解导致的分子细节。通过研究 AmpC 头孢菌素酶、ADC-7（不动杆菌衍生的头孢菌素酶）和鲍曼不动杆菌的外排泵，我们的工作解决了成功的 β-内酰胺治疗的最重要障碍。分析含有不同 R1 和 R2 侧链的特定硼酸抑制剂 (BAI) 如何灭活 ADC-7 我们的方法将需要动力学。和生物物理（等温量热法、蛋白质热稳定性和圆二色性）测量将补充结构表征，我们将共同获得对失活机制、定义有效抑制剂的能量要求的独特见解，并了解…的演变。一旦确定了 BAI 的特征并确定了每个 BAI/ADC-7 复合物的结构，我们还将通过对与 BAI 相互作用的氨基酸残基进行定点诱变来测试我们的结论。测试这些变化对敏感性、动力学、蛋白质稳定性和结构的影响，这种综合方法将揭示哪些氨基酸位置：(a) 对 BAI 和 β-内酰胺化合物的结合很重要；(b) 对酶结构至关重要； 、稳定性和/或功能。我们的努力将为新型 BAI 的开发和优化提供合理的基础，与这些研究相结合，我们将定义迄今为止未表征的外排泵在β-内酰胺/BAI 耐药性中的作用。利用 AdeABC 和 AdeIJK (adeABC/adeIJK) 的“敲除”，我们将探索“二级”外排泵和转运蛋白在 β-内酰胺耐药性中的作用，在影响 β-内酰胺耐药性的两个领域实现这些目标将有助于我们设计更有效的药物。 �-内酰胺对抗鲍曼不动杆菌。此外，我们的工作是理解为什么鲍曼不动杆菌的外排系统呈现出强大的“第一步”整合这些知识将提供有关β-内酰胺耐药性的必要见解，这将有助于药物化学家和医生应对这种严重的传染病威胁。